Mariana Alves1,2,3,4, Patrícia Pita Lobo4,5, Linda Azevedo Kauppila5, Leonor Rebordão6, M Manuela Cruz7, Carla Guerreiro8,9, José M Ferro2,4,5, Joaquim J Ferreira2,3,4,10, Sofia Reimão2,3,4,8,9. 1. Serviço de Medicina III, 70896Hospital Pulido Valente (CHULN), Lisboa, Portugal. 2. Avenida Professor Egas Moniz, Faculty of Medicine, 89237University of Lisbon, Lisbon, Portugal. 3. Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, 89237Universidade de Lisboa, Lisbon, Portugal. 4. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisbon, Lisbon, Portugal. 5. Departamento de Neurociências e Saúde Mental, CHULN, Lisbon, Portugal. 6. 89237Hospital Fernando da Fonseca, Lisbon, Portugal. 7. Unidade de Saúde Familiar Benfica Jardim, 89237ACES Lisboa Norte, Lisbon, Portugal. 8. Neurological Imaging Department, 89237Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal. 9. Imaging University Clinic, Faculdade de Medicina, 89237Universidade de Lisboa, Lisbon, Portugal. 10. CNS - Campus Neurológico Sénior, Lisbon, Portugal.
Abstract
BACKGROUND AND PURPOSE: The cardiovascular risk in Parkinson's disease (PD) remains uncertain and controversial. Some studies suggest PD patients present an increased risk of cerebrovascular disease. We aimed to study the prevalence of neuroimaging cerebrovascular biomarkers in PD patients compared to controls, using an accurate and complete magnetic resonance (MR) imaging evaluation. MATERIAL AND METHODS: Neuroimaging sub-study within a larger cross-sectional case-control study. An enriched subgroup of PD patients (≤10 years since diagnosis) with at least a moderate cardiovascular mortality risk based on a Systematic COronary Risk Evaluation (SCORE) was compared to community-based controls regarding neuroimaging biomarkers. Patients underwent a high-resolution T1-weighted MR imaging sequence at 3.0 T to visualize neuromelanin. A 3D SWI FFE, sagittal 3D T1-weighted, axial FLAIR and diffusion-weighted image sequences were obtained. RESULTS: The study included 47 patients, 24 with PD and 23 controls. PD patients presented a reduced area and signal intensity of the substantia nigra and locus coeruleus on neuromelanin-sensitive MR. The median SCORE was 5% in both groups. No significant differences regarding white matter hyperintensities (OR 4.84, 95% CI 0.50, 47.06), lacunes (OR 0.43, 95% CI 0.07, 2.63), microbleeds (OR 0.64, 95% CI 0.13, 3.26), or infarcts (0.95, 95% CI 0.12, 7.41) was found. The frequency of these neuroimaging biomarkers was very low in both groups. CONCLUSION: The present study does not support an increased prevalence of neuroimaging cerebrovascular biomarkers in PD patients.
BACKGROUND AND PURPOSE: The cardiovascular risk in Parkinson's disease (PD) remains uncertain and controversial. Some studies suggest PD patients present an increased risk of cerebrovascular disease. We aimed to study the prevalence of neuroimaging cerebrovascular biomarkers in PD patients compared to controls, using an accurate and complete magnetic resonance (MR) imaging evaluation. MATERIAL AND METHODS: Neuroimaging sub-study within a larger cross-sectional case-control study. An enriched subgroup of PD patients (≤10 years since diagnosis) with at least a moderate cardiovascular mortality risk based on a Systematic COronary Risk Evaluation (SCORE) was compared to community-based controls regarding neuroimaging biomarkers. Patients underwent a high-resolution T1-weighted MR imaging sequence at 3.0 T to visualize neuromelanin. A 3D SWI FFE, sagittal 3D T1-weighted, axial FLAIR and diffusion-weighted image sequences were obtained. RESULTS: The study included 47 patients, 24 with PD and 23 controls. PD patients presented a reduced area and signal intensity of the substantia nigra and locus coeruleus on neuromelanin-sensitive MR. The median SCORE was 5% in both groups. No significant differences regarding white matter hyperintensities (OR 4.84, 95% CI 0.50, 47.06), lacunes (OR 0.43, 95% CI 0.07, 2.63), microbleeds (OR 0.64, 95% CI 0.13, 3.26), or infarcts (0.95, 95% CI 0.12, 7.41) was found. The frequency of these neuroimaging biomarkers was very low in both groups. CONCLUSION: The present study does not support an increased prevalence of neuroimaging cerebrovascular biomarkers in PD patients.
Authors: Joan Martí-Fàbregas; Santiago Medrano-Martorell; Elisa Merino; Luis Prats-Sánchez; Rebeca Marín; Raquel Delgado-Mederos; Alejandro Martínez-Domeño; Pol Camps-Renom; Elena Jiménez-Xarrié; Mariluisa Zedde; Manuel Gómez-Choco; Lidia Lara; Amèlia Boix; Ana Calleja; Ana María De Arce-Borda; Yolanda Bravo; Blanca Fuentes; María Hernández-Pérez; David Cánovas; Laura Llull; Beatriz Zandio; Marimar Freijo; Ignacio Casado-Naranjo; Jordi Sanahuja; Dolores Cocho; Jerzy Krupinski; Ana Rodríguez-Campello; Ernest Palomeras; Alicia De Felipe; Marta Serrano; Elena Zapata-Arriaza; Josep Zaragoza-Brunet; Inmaculada Díaz-Maroto; Jessica Fernández-Domínguez; Aida Lago; José Maestre; Manuel Rodríguez-Yáñez; Ignasi Gich Journal: Neurology Date: 2019-04-19 Impact factor: 9.910
Authors: Turi O Dalaker; Jan P Larsen; Niels Bergsland; Mona K Beyer; Guido Alves; Michael G Dwyer; Ole-Bjorn Tysnes; Ralph H B Benedict; Arpad Kelemen; Kolbjorn Bronnick; Robert Zivadinov Journal: Mov Disord Date: 2009-11-15 Impact factor: 10.338